227 related articles for article (PubMed ID: 35735062)
1. Global trends of dalbavancin: A bibliometric analysis.
Monteagudo-Martínez N; Solís García Del Pozo J; Ikuta I; Galindo MF; Jordán J
J Clin Pharm Ther; 2022 Sep; 47(9):1299-1311. PubMed ID: 35735062
[TBL] [Abstract][Full Text] [Related]
2. New lipoglycopeptides: a comparative review of dalbavancin, oritavancin and telavancin.
Zhanel GG; Calic D; Schweizer F; Zelenitsky S; Adam H; Lagacé-Wiens PR; Rubinstein E; Gin AS; Hoban DJ; Karlowsky JA
Drugs; 2010 May; 70(7):859-86. PubMed ID: 20426497
[TBL] [Abstract][Full Text] [Related]
3. A Bibliometric Evaluation of the Top 100 Cited Dimethyl Fumarate Articles.
García-Fernández FJ; García-Fernández AE; Ikuta I; Nava E; Solis García Del Pozo J; Jordan J; Galindo MF
Molecules; 2021 Feb; 26(4):. PubMed ID: 33669498
[TBL] [Abstract][Full Text] [Related]
4. A bibliometric evaluation of the top 100 cited natalizumab articles.
García-Fernández FJ; García-Fernández AE; Nava E; Del Pozo JSG; Ikuta I; Jordan J; Galindo MF
J Neuroimmunol; 2020 Dec; 349():577379. PubMed ID: 33007648
[TBL] [Abstract][Full Text] [Related]
5. A comparative review of the lipoglycopeptides: oritavancin, dalbavancin, and telavancin.
Guskey MT; Tsuji BT
Pharmacotherapy; 2010 Jan; 30(1):80-94. PubMed ID: 20030476
[TBL] [Abstract][Full Text] [Related]
6. Activity of dalbavancin tested against Gram-positive clinical isolates causing skin and skin-structure infections in paediatric patients from US hospitals (2014-2015).
Pfaller MA; Mendes RE; Sader HS; Castanheira M; Flamm RK
J Glob Antimicrob Resist; 2017 Dec; 11():4-7. PubMed ID: 28735053
[TBL] [Abstract][Full Text] [Related]
7. The 100 Most-Cited Articles in COVID-19 Vaccine Hesitancy Based on Web of Science: A Bibliometric Analysis.
Liu B; You J; Huang L; Chen M; Shen Y; Xiong L; Zheng S; Huang M
Infect Drug Resist; 2023; 16():2625-2646. PubMed ID: 37159828
[TBL] [Abstract][Full Text] [Related]
8. Dalbavancin for the treatment of acute bacterial skin and skin structure infections.
Ramdeen S; Boucher HW
Expert Opin Pharmacother; 2015; 16(13):2073-81. PubMed ID: 26239321
[TBL] [Abstract][Full Text] [Related]
9. Beyond Vancomycin: The Tail of the Lipoglycopeptides.
Klinker KP; Borgert SJ
Clin Ther; 2015 Dec; 37(12):2619-36. PubMed ID: 26658277
[TBL] [Abstract][Full Text] [Related]
10. Dalbavancin in the treatment of acute bacterial skin and skin structure and other infections: a safety evaluation.
Righi E; Visentin A; Meroi M; Carrara E; Tacconelli E
Expert Opin Drug Saf; 2022 Sep; 21(9):1171-1181. PubMed ID: 36093622
[TBL] [Abstract][Full Text] [Related]
11. The current and future off-label uses of dalbavancin: a narrative review.
De Vito A; Fiore V; Colpani A; Zauli B; Fanelli C; Tiseo G; Occhineri S; Babudieri S; Falcone M; Madeddu G
Eur Rev Med Pharmacol Sci; 2023 Feb; 27(3):1222-1238. PubMed ID: 36808371
[TBL] [Abstract][Full Text] [Related]
12. Once-weekly dalbavancin versus daily conventional therapy for skin infection.
Boucher HW; Wilcox M; Talbot GH; Puttagunta S; Das AF; Dunne MW
N Engl J Med; 2014 Jun; 370(23):2169-79. PubMed ID: 24897082
[TBL] [Abstract][Full Text] [Related]
13. One hundred most cited article related to pancreaticoduodenectomy surgery: A bibliometric analysis.
He R; Yin T; Pan S; Wang M; Zhang H; Qin R
Int J Surg; 2022 Aug; 104():106775. PubMed ID: 35840048
[TBL] [Abstract][Full Text] [Related]
14. Top 100 Most Cited Papers in Laser-Assisted in situ Keratomileusis Surgery: A Bibliometric Analysis.
Flynn E; Pakhchanian H; Sohal P; Gupta R; Raiker R; Asahi MG; Belyea D
Semin Ophthalmol; 2022 May; 37(4):531-537. PubMed ID: 35188852
[TBL] [Abstract][Full Text] [Related]
15. Experience with dalbavancin use in various gram-positive infections within Aberdeen Royal Infirmary OPAT service.
McSorley JC; Reyes D; Tonna I; Bateman V
Infection; 2024 Apr; 52(2):567-576. PubMed ID: 38165594
[TBL] [Abstract][Full Text] [Related]
16. Dalbavancin and telavancin: novel lipoglycopeptides for the treatment of Gram-positive infections.
Zhanel GG; Trapp S; Gin AS; DeCorby M; Lagacé-Wiens PR; Rubinstein E; Hoban DJ; Karlowsky JA
Expert Rev Anti Infect Ther; 2008 Feb; 6(1):67-81. PubMed ID: 18251665
[TBL] [Abstract][Full Text] [Related]
17. Multiple Weekly Dalbavancin Dosing for the Treatment of Native Vertebral Osteomyelitis Caused by Methicillin-Resistant Staphylococcus Aureus: A Case Report.
Almangour TA; Fletcher V; Alessa M; Alhifany AA; Tabb D
Am J Case Rep; 2017 Dec; 18():1315-1319. PubMed ID: 29222405
[TBL] [Abstract][Full Text] [Related]
18. Dalbavancin for the treatment of acute bacterial skin and skin structure infections.
Esposito S; Noviello S; Leone S
Infez Med; 2015 Dec; 23(4):313-7. PubMed ID: 26700080
[TBL] [Abstract][Full Text] [Related]
19. Update on activity of dalbavancin and comparators against clinical isolates of Gram-positive pathogens from Europe and Russia (2017-2018), and on clonal distribution of MRSA.
Riccobono E; Giani T; Baldi G; Arcangeli S; Antonelli A; Tellone V; Del Vecchio A; De Joannon AC; Rossolini GM
Int J Antimicrob Agents; 2022 Feb; 59(2):106503. PubMed ID: 34929289
[TBL] [Abstract][Full Text] [Related]
20. Multicenter evaluation of the in vitro activity of dalbavancin tested against staphylococci and streptococci in 5 European countries: results from the DECIDE Surveillance Program (2007).
Biedenbach DJ; Jones RN
Diagn Microbiol Infect Dis; 2009 Jun; 64(2):177-84. PubMed ID: 19249179
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
